Secondary Logo

Institutional members access full text with Ovid®

Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate

La Porta, Carmena,1; Bura, Simona Andreeaa,1; Aracil-Fernández, Auxiliadorab; Manzanares, Jorgeb; Maldonado, Rafaela,*

Section Editor(s):

doi: 10.1016/j.pain.2012.10.009
Article
Buy
SDC

Summary CB2 cannabinoid receptor plays a crucial role in the development of joint pain induced by monosodium iodoacetate in mice.

Joint pain is a common clinical problem for which both inflammatory and degenerative joint diseases are major causes. The purpose of this study was to investigate the role of CB1 and CB2 cannabinoid receptors in the behavioral, histological, and neurochemical alterations associated with joint pain. The murine model of monosodium iodoacetate (MIA) was used to induce joint pain in knockout mice for CB1 (CB1KO) and CB2 cannabinoid receptors (CB2KO) and transgenic mice overexpressing CB2 receptors (CB2xP). In addition, we evaluated the changes induced by MIA in gene expression of CB1 and CB2 cannabinoid receptors and μ-, δ- and κ-opioid receptors in the lumbar spinal cord of these mice. Wild-type mice, as well as CB1KO, CB2KO, and CB2xP mice, developed mechanical allodynia in the ipsilateral paw after MIA intra-articular injection. CB1KO and CB2KO demonstrated similar levels of mechanical allodynia of that observed in wild-type mice in the ipsilateral paw, whereas allodynia was significantly attenuated in CB2xP. Interestingly, CB2KO displayed a contralateral mirror image of pain developing mechanical allodynia also in the contralateral paw. All mouse lines developed similar histological changes after MIA intra-articular injection. Nevertheless, MIA intra-articular injection produced specific changes in the expression of cannabinoid and opioid receptor genes in lumbar spinal cord sections that were further modulated by the genetic alteration of the cannabinoid receptor system. These results revealed that CB2 receptor plays a predominant role in the control of joint pain manifestations and is involved in the adaptive changes induced in the opioid system under this pain state.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

aLaboratori de Neurofarmacologia, Facultat de Ciències de la Salut i de la Vida, Universitat Pompeu Fabra, C/Dr. Aiguader, 88, 08003 Barcelona, Spain

bInstituto de Neurociencias, Universidad Miguel Hernández-CSIC, Av. Ramon y Cajal, s/n, 03550, San Juan de Alicante, Alicante, Spain

*Corresponding author. Tel.: +34 933160824; fax: +34 933160901.

E-mail address:rafael.maldonado@upf.edu

1These two authors contributed equally to this work, and both should be considered first author.

Article history: Received 5 June 2012; Received in revised form 3 August 2012; Accepted 18 October 2012.

© 2013 Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website